{"url_path":"/sec/kblb/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1413119/0001493152-26-023130-index.html","accession_number":"0001493152-26-023130","cik":"0001413119","ticker":"KBLB","issuer_name":"Kraig Biocraft Laboratories, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1413119/0001493152-26-023130-index.html","primary_entity_key":"0001413119","primary_entity_name":"Kraig Biocraft Laboratories, Inc."},"word_count":52,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\n(a)\nNot applicable.\n\n \n\n(b)\nNone.\n\n \n\n(c)\nDuring the three months ended March 31, 2026, no director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1\ntrading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation\nS-K.\n\n \n\n39"}